Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study
Authors:
- Satoshi IkedaSatoshi Ikeda
- Machiko AritaMAMachiko Arita
- Kenta MisakiKMKenta Misaki
- Shohei MishimaSMShohei Mishima
- Takuya TakaiwaTTTakuya Takaiwa
- Akihiro NishiyamaANAkihiro Nishiyama
- Akihiro ItoAIAkihiro Ito
- Kenjiro FurutaKFKenjiro Furuta
- Toshihide YokoyamaTYToshihide Yokoyama
- Fumiaki TokiokaFTFumiaki Tokioka
- Maki NoyamaMNMaki Noyama
- Hiroshige YoshiokaHYHiroshige Yoshioka
Open Access
- 28 May 2015
- journal article
- research article
- Published by Springer Nature in SpringerPlus
- Vol. 4 (1) , 1-11
Abstract
The aims of this study were to retrospectively review Japanese consecutive cases of polymyositis (PM), dermatomyositis (DM), and clinically amyopathic dermatomyositis (CADM), focusing on interstital lung disease (ILD) and malignancy, and to document any differences in the incidence, clinical features, and impact on prognosis among patients with PM, DM, and CADM. We retrospectively reviewed 62 consecutive patients diagnosed with PM, DM, and CADM according to Bohan and Peter’s criteria (PM/DM) and Sontheimer’s criteria and Gerami’s criteria (CADM), focusing on ILD and malignancy. ILD occurrence rates were 48 % (11/23) in patients with PM, 46 % (11/24) in DM, and 100 % (15/15) in CADM. Malignancy occurred during diagnosis or the observation period in 14 patients; 86 % were without ILD, and 64 % were DM without ILD. Multivariate logistic regression analysis showed that the risk of newly diagnosed malignancy was significantly lower in patients with ILD [odds ratio, 0.0688; 95 % confidence interval (CI), 0.00127–0.372; p = 0.00190] and significantly higher in patients with DM (odds ratio, 5.21; 95 % CI, 1.17–23.1; p = 0.0299) than in other patients. Patients with malignancies had shorter survival than those without malignancies; no clinically meaningful difference in survival was observed among the different myositis types and for presence of ILD. In CADM-ILD, 80 % fatal cases died from refractory ILD ≤90 days from the first visit; neither death nor recurrence occurred subsequently. In conclusion, a positive association between DM and malignancy and a negative association between ILD and malignancy were noted. In the present study, malignancy was a predictor of poor long-term prognosis, but ILD were not. ILD associated with CADM contributed greatly to poor short-term prognosis, but neither death nor recurrence occurred subsequently.Keywords
This publication has 43 references indexed in Scilit:
- Interstitial Lung Disease in Classic and Skin-Predominant DermatomyositisArchives of Dermatology, 2010
- Polymyositis, dermatomyositis and malignancy: A further intriguing linkAutoimmunity Reviews, 2010
- Malignancy Is Associated with Dermatomyositis But Not Polymyositis in Northern New England, USAThe Journal of Rheumatology, 2009
- Interstitial lung disease in polymyositis and dermatomyositis: Longitudinal evaluation by pulmonary function and radiologyArthritis Care & Research, 2008
- The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositisAnnals of the Rheumatic Diseases, 2007
- Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort studyClinical Rheumatology, 2007
- A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): A missing link within the spectrum of the idiopathic inflammatory myopathiesJournal of the American Academy of Dermatology, 2006
- Dermatomyositis Associated with Rapidly Progressive Fatal Interstitial Pneumonitis and Pneumomediastinum: CASE REPORTScandinavian Journal of Rheumatology, 1999
- Risk of Cancer in Patients with Dermatomyositis or PolymyositisNew England Journal of Medicine, 1992
- A New Approach to the Classification of Idiopathic Inflammatory MyopathyMedicine, 1991